Access the full text.
Sign up today, get DeepDyve free for 14 days.
H Esterbauer, F Krempler, H Oberkofler, W Patsch (1999)
The complement system: a pathway linking host defence and adipocyte biologyEur J Clin Invest, 29
BR Brooks, RG Miller, M Swash, TL Munsat (2000)
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord, 1
T Philips, W Robberecht (2011)
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron diseaseLancet Neurol, 10
J Liu, L Gao, D Zang (2015)
Elevated levels of IFN-? in CSF and serum of patients with amyotrophic lateral sclerosisPLoS One, 10
J Thundyil, D Pavlovski, CG Sobey, TV Arumugam (2012)
Adiponectin receptor signalling in the brainBr J Pharmacol, 165
P Vercruysse, J Sinniger, H Oussini, J Scekic-Zahirovic, S Dieterlé, R Dengler (2016)
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosisBrain, 139
A Schmid, A Hochberg, M Berghoff, J Schlegel, T Karrasch, M Kaps, A Schäffler (2015)
Quantification and regulation of adipsin in human cerebrospinal fluid (CSF)Clin Endocrinol (Oxf), 84
G Fantuzzi (2013)
Adiponectin in inflammatory and immune-mediated diseasesCytokine, 64
PA McCombe, RD Henderson (2011)
The role of immune and inflammatory mechanisms in ALSCurr Mol Med, 11
M Tanaka, H Kikuchi, T Ishizu, M Minohara, M Osoegawa, K Motomura (2006)
Intrathecal upregulation of G-CSF and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosisJ Neuropathol Exp Neurol, 65
DR Beers, W Zhao, B Liao, O Kano, J Wang, A Huang (2011)
Neuroinflammation modulates distinct regional and temporal clinical responses in ALSBrain Behav Immun, 25
DR Gustafson (2010)
Adiposity hormones and dementiaJ Neurol Sci, 299
PF Pradat, G Bruneteau, PH Gordon, L Dupuis, D Bonnefont-Rousselot, D Simon (2010)
Impaired glucose tolerance in patients with amyotrophic lateral sclerosisAmyotroph Lateral Scler, 11
U Musabak, S Demirkaya, G Genç, RS Ilikci, Z Odabasi (2011)
Serum adiponectin, TNF-?, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimensNeuroimmunomodulation, 18
J Ravits, S Appel, RH Baloh (2013)
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesisAmyotroph Lateral Scler Frontotemporal Degener, 14
W Zhao, DR Beers, SH Appel (2013)
Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosisJ Neuroimmune Pharmacol, 8
Y Yang, W Hu, S Jiang, B Wang, Y Li, C Fan (2015)
The emerging role of adiponectin in cerebrovascular and neurodegenerative diseasesBiochim Biophys Acta, 1852
P Kaufmann, G Ley, JL Thompson, ML Delbene, V Battista, PH Gordon (2005)
The ALSFRSr predicts survival time in an ALS clinic populationNeurology, 64
TM Woodruff, KJ Costantini, SM Taylor, PG Noakes (2008)
Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitorsAdv Exp Med Biol, 632
MH Toft, O Gredal, B Pakkenberg (2005)
The size distribution of neurons in the motor cortex in amyotrophic lateral sclerosisJ Anat, 207
SP Ringel, JR Murphy, MK Alderson, W Bryan, JD England, RG Miller (1993)
The natural history of amyotrophic lateral sclerosisNeurology, 43
KR Mills (2003)
The natural history of central motor abnormalities in amyotrophic lateral sclerosisBrain, 136
F Schmitt, G Hussain, L Dupuis, JP Loeffler, A Henriques (2014)
A plural role for lipids in motor neuron diseases: energy, signaling and structureFront Cell Neurosci, 8
R Gomeni, M Fava (2014)
Amyotrophic lateral sclerosis disease progression modelAmyotroph Lateral Scler Frontotemporal Degener, 15
A Henriques, H Blasco, MC Fleury, P Corcia, A Echaniz-Laguna, L Robelin (2015)
Blood cell palmitoleate?palmitate ratio is an independent prognostic factor for amyotrophic lateral sclerosisPLoS One, 10
A Hietaharju, H Kuusisto, R Nieminen, K Vuolteenaho, I Elovaara, E Moilanen (2010)
Elevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: a Finnish co-twin studyEur J Neurol, 17
Amyotrophic lateral sclerosis (ALS) is described as a neurodegenerative disorder. However, neuroinflammation and chemokine expression are prominent pathological finding at sites of injury. Adipsin and adiponectin are molecules that are implicated in the pathogenesis of neurodegenerative and neuroimmune disorders. Adipsin and adiponectin concentrations were determined in the CSF of ALS patients and controls and the relationship of these chemokines with clinical severity and disease duration in ALS was determined. Seventy-seven ALS patients (mean age 49.5 ± 10.4 years) (mean body mass index 23.5 ± 4.5) were included. Twenty patients had bulbar, 53 spinal, and four bulbospinal onset ALS. Median adipsin CSF level was 12,650.94 pg/ml in ALS patients and 3290.98 pg/ml in controls (p < 0.001). Median adiponectin CSF level was 4608 pg/ml in ALS patients and 3453 pg/ml in controls (p = 0.1). No differences were observed in disease duration, progression rate or disease severity. There was a significant positive correlation between adipsin and adiponectin concentrations (r = 0.379, p = 0.01). No correlation with age, body mass index or ALFRS-R score was found. Adipsin was significantly elevated in CSF, suggesting that this chemokine might have a role in ALS pathogenesis. Adiponectin showed a trend towards higher concentrations, but failed to reach statistical significance. Due to the clinical heterogeneity in our cohort, these chemokines do not appear to be associated with disease duration or severity.
Acta Neurologica Belgica – Springer Journals
Published: May 26, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.